Paper29909019
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P and 12 others. Gastroenterology, 2018. Cited by 155 papers, by iCite.
Cite this record
ConductScience Library. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Papers, record 29909019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29909019
- Disease
- Crohn disease198 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents | Major topic |
| Colon | Major topic |
| Colonoscopy | Major topic |
| Crohn Disease | Major topic |
| Gastrointestinal Agents | Major topic |
| Ustekinumab | Major topic |
| Wound Healing | Major topic |
| Administration, Intravenous | |
| Adult | |
| Female | |
| Humans | |
| Induction Chemotherapy | |
| Maintenance Chemotherapy | |
| Male | |
| Middle Aged | |
| Predictive Value of Tests | |
| Prospective Studies | |
| Remission Induction | |
| Severity of Illness Index | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01369329 | A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT01369342 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT01369355 | A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) | Derived from the trial | Yes | ClinicalTrials.gov |
Cited by90
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 155 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42899159 | The aryl hydrocarbon receptor and kynurenine pathway: connecting inflammatory bowel disease and depression via the microbiota gut brain axis. | Front Neurosci | 2026 | https://conductscience.org/library/papers/42899159 | PubMed |
| 42609442 | Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42609442 | PubMed |
| 42205859 | A decade of clinical data with vedolizumab: the past, present, and future. | Ther Adv Gastroenterol | 2026 | https://conductscience.org/library/papers/42205859 | PubMed |
| 42195154 | A Comparative Study of Different Biological Drugs in First-Line Therapy in Crohn's Disease: A Multicenter Descriptive Analysis. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42195154 | PubMed |
| 41930211 | Analysis of the use of monoclonal antibodies in the treatment of Crohn's disease. | Antib Ther | 2026 | https://conductscience.org/library/papers/41930211 | PubMed |
| 41852927 | Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial. | EClinicalMedicine | 2026 | https://conductscience.org/library/papers/41852927 | PubMed |
| 41843763 | Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg. | J Crohns Colitis | 2026 | https://conductscience.org/library/papers/41843763 | PubMed |
| 41553714 | Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. | Adv Ther | 2026 | https://conductscience.org/library/papers/41553714 | PubMed |
| 41458359 | Development of Predictive Models for Long-Term Endoscopic Response to Ustekinumab in Crohn's Disease Based on Plasma Proteomics. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/41458359 | PubMed |
| 41339249 | Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. | Ann Med | 2025 | https://conductscience.org/library/papers/41339249 | PubMed |
| 41002400 | Predictive Role of MicroRNAs in the Diagnosis and Management of Patients with Crohn's Disease: A Clinician's View. | Cells | 2025 | https://conductscience.org/library/papers/41002400 | PubMed |
| 40722847 | Insights into the Molecular Mechanisms and Novel Therapeutic Strategies of Stenosis Fibrosis in Crohn's Disease. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722847 | PubMed |
| 40708467 | Imbalance between skeletal muscle and intermuscular fat predicts treatment failure in Crohn's disease: an imaging biomarker for risk stratification. | Ann Med | 2025 | https://conductscience.org/library/papers/40708467 | PubMed |
| 40693590 | Effectiveness, treatment pattern, and safety of ustekinumab in treating bio-naïve patients with Crohn's disease in the real-world clinical setting in China. | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/40693590 | PubMed |
| 40417421 | Short-Term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Real-World Retrospective Multicenter Study in China. | Int J Gen Med | 2025 | https://conductscience.org/library/papers/40417421 | PubMed |
| 40323342 | Differentiating IL-23 Inhibitors in Crohn's Disease. | Drugs | 2025 | https://conductscience.org/library/papers/40323342 | PubMed |
| 40243170 | Pancreatic Enzyme Replacement Therapy Improves Exclusive Enteral Nutrition Related Diarrhea in Crohn's Disease: A Prospective Randomized Trial. | United European Gastroenterol J | 2025 | https://conductscience.org/library/papers/40243170 | PubMed |
| 40186719 | Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40186719 | PubMed |
| 40142602 | Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn's Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study. | J Clin Med | 2025 | https://conductscience.org/library/papers/40142602 | PubMed |
| 39990514 | What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease? | J Can Assoc Gastroenterol | 2025 | https://conductscience.org/library/papers/39990514 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| USTEKINUMAB | CHEMBL1201835 | Derived from the trial | 3 | https://conductscience.org/library/drugs/CHEMBL1201835 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29909019
GET https://conductscience.org/api/papers/v1/29909019/cited_by?page=2